References (continued)

36. Nakeeb A, Pitt HA. Radiation therapy, chemotherapy and chemoradiation in hilar cholangiocarcinoma. HPB (Oxford) 2005;7(4):278–82. [PMC free article] [PubMed]

Continue Reading

37. Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol. 2012;30:1934–40. [PubMed]

38. Takada T, Nimura Y, Katoh H, et al. Prospective randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C for non-resectable pancreatic and biliary carcinoma: multicentre randomized trial. Hepatogastroenterology. 1998;45:2020–6.[PubMed]

39. Murakami Y, Uemura K, Sudo T, et al. Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma. Surg Oncol. 2011;18:651–8. [PubMed]

40. Neoptolemos JP, Moore MJ, Cox TF, et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs. observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA. 2012;308:147–56. [PubMed]

41. Bridgewater JA, Stubbs C, Stocken DD, Fox RP, Primrose JN. BILCAP: a randomized clinical trial evaluating adjuvant chemotherapy with capecitabine compared to expectant treatment alone following curative surgery for biliary tract cancers. J Clin Oncol. 2011 Abstr4125.

42. Fujiwara Y, Kobayashi S, Nagano H, et al. Pharmacokinetic study of adjuvant gemcitabine therapy for biliary tract cancer following major hepatectomy (KHBO1101) PLoS One. 2015;10(12):e0143072. [PMC free article] [PubMed]

43. Kobayashi S, Nagano H, Sakai D, et al. Phase I study of adjuvant gemcitabine or S-1 in patients with biliary tract cancers undergoing major hepatectomy: KHBO1003 study. Cancer Chemother Pharmacol. 2014;74(4):699–709. [PubMed]

44. Yamanaka K, Hatano E, Kanai M, et al. A single-center analysis of the survival benefits of adjuvant gemcitabine chemotherapy for biliary tract cancer. Int J Clin Oncol. 2014;19(3):485–9. [PubMed]

45. Kobayashi S, Miyamoto A, Shimizu J, et al. Comparison of 4-weekly vs. 3-weekly gemcitabine as adjuvant chemotherapy following curative resection for biliary tract cancer: a prospective randomized controlled trial. J Cancer Ther. 2011;2:703–9.

46. Kainuma O, Miura F, Furukawa D, et al. Feasibility and efficacy of gemcitabine plus cisplatin combination therapy after curative resection for biliary tract cancer. J Hepatobiliary Pancreat Sci. 2015;22(11):789–94. [PubMed]

47. Toyoda M, Ajiki T, Fujiwara Y, et al. Phase I study of adjuvant chemotherapy with gemcitabine plus cisplatin in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1004) Cancer Chemother Pharmacol. 2014;73(6):1295–301. [PMC free article] [PubMed]

48. Jiang W, Zeng ZC, Tang ZY, et al. Benefit of radiotherapy for 90 patients with resected intrahepatic cholangiocarcinoma and concurrent lymph node metastases. J Cancer Res Clin Oncol. 2010;136:1323–31. [PubMed]

49. Gwak HK, Kim WC, Kim HJ, Park JH. Extrahepatic bile duct cancers: surgery alone versus surgery plus postoperative radiation therapy. Int J Radiat Oncol Biol Phys. 2010;78(1):194–8. [PubMed]

50. González González D, Gouma DJ, Rauws EA, van Gulik TM, Bosma A, Koedooder C. Role of radiotherapy, in particular intraluminal brachytherapy, in the treatment of proximal bile duct carcinoma. Ann Oncol. 1999;10(suppl 4):215–20. [PubMed]

51. Czito BG, Anscher MS, Willett CG. Radiation therapy in the treatment of cholangiocar-cinoma. Oncology (Williston Park) 2006;20(8):873–84. discussion 886–8, 893–5. [PubMed]

52. Kim S, Kim SW, Bang YJ, Heo DS, Ha SW. Role of postoperative radiotherapy in the management of extrahepatic bile duct cancer. Int J Radiat Oncol Biol Phys. 2002;54(2):414–9.[PubMed]

53. Nakeeb A, Pitt HA. Radiation therapy, chemotherapy and chemoradiation in hilar cholangiocarcinoma. HPB (Oxford) 2005;7(4):278–82. [PMC free article] [PubMed]

54. Ben-Josef E, Guthrie KA, El-Khoueiry AB, et al. SWOG S0809: a phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. J Clin Oncol. 2014(60):2219. [PMC free article] [PubMed]

55. Ramirez-Merino N, Ponce Aix S, Cortes-Funes H. Chemotherapy for cholangiocarcinoma. An update. World J Gastrointest Cancer. 2013;15(7):171–6.

56. Shen WF, Zhong W, Liu Q, Sui CJ, Huang YQ, Yang JM. Adjuvant trans-catheter arterial chemoembolization for intrahepatic cholangiocarcinoma after curative surgery: retrospective control study. World J Surg. 2011;35:2083–91. [PubMed]

57. Kuhlmann JB, Euringer W, Spangenberg HC, et al. Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy. Eur J Gastroenterol Hepatol. 2012;24(4):437–43. [PubMed]

58. Dougherty TJ, Gomer CJ, Henderson BW, et al. Photodynamic therapy. J Natl Cancer Inst. 1998;90:889–905. [PMC free article][PubMed]

59. Nanashima A, Yamaguchi H, Shibasaki S, et al. Adjuvant photodynamic therapy for bile duct carcinoma after surgery: a preliminary study. J Gastroenterol. 2004;39:1095–101. [PubMed]

60. Lee TY, Cheon YK, Shim CS. Current status of photodynamic therapy for bile duct cancer. Clin Endosc. 2013;46(1):38–44.[PMC free article] [PubMed]

Source: Clinical Medicine Insights.
Originally published May 12, 2016.